The British Medical Association (BMA) has called for the Office of Fair Trading (OFT) to extend its private healthcare market review to include insurers' fee schedules.
Medical insurance brokers have branded Defacto's new private medical insurance (PMI) star ratings as ‘highly dangerous and not in the best interest of customers'.
Axa PPP has extended its cancer coverage to include the clinically effective prostate cancer drug rejected for the NHS because it is too expensive.
Cancer charities have slammed the National Institute for Health and Clinical Excellence's (Nice) decision to reject a drug that prolongs the life of prostate cancer suffers for being too expensive.
Defaqto has released its Star Ratings for private medical insurance (PMI) for the first time.
Critical illness (CI) and mortgage payment protection insurance (MPPI) are among the most complicated financial products for consumers to understand, the ABI has found.
The coming year promises to be a tough one for the private healthcare sector, according to a new report from analyst Laing and Buisson.
Healix has voiced support for the use of open referrals within the private medical insurance (PMI) market but warned that insurers need to be more transparent about the process.
Universal Provident has launched a new combined protection and health insurance product aimed at customers forced to reduce their cover limits.
The Association of Medical Insurance Intermediaries (Amii) has announced 500 people have now passed the Chartered Insurance Institute (CII)/AMII IF7 private medical insurance (PMI) exam.